Healthcare
Live Price
Offline$36.95
+1.01% today
1Y Change
-21.69%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Qiagen N.V. (QGEN) is a Healthcare stock with a market cap of $7.06B and listed on NYSE. The stock last traded around $36.95 and down 21.7% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +5.7%, EPS growth of +423.1%, a dividend yield of 7.4%. What stands out right now is revenue +5.7%, EPS +423.1%, free cash flow -10.5% with operating margin 24.9% and ROIC 7.8%. The dividend matters to the case here, with a current yield around 7.4%. Valuation is more restrained than many high-expectation growth names at P/E 16.7 and price/sales 3.4. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines QGEN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
QGEN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
QGEN Max Drawdown
-41.38%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for QGEN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.3B
+5.1% YoY
FY Net Income
$512.6M
+21.1% YoY
Free Cash Flow
$432.5M
-23.6% YoY
Revenue Growth
+5.7%
EPS Growth
+423.1%
Gross Margin
61.8%
Net Margin
20.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.1B | 2.0B | 2.0B | 2.1B | 2.3B |
| Gross Profit | 1.3B | 967M | 1.2B | 1.4B | 1.5B |
| Operating Income | 520M | 98M | 410M | 531M | 630M |
| EBITDA | 717M | 368M | 689M | 779M | 895M |
| Net Income | 425M | 84M | 341M | 423M | 513M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 839M | 664M | 668M | 731M | 881M |
| Total Assets | 6.3B | 5.7B | 6.1B | 6.3B | 6.1B |
| Total Liabilities | 2.5B | 2.1B | 2.3B | 2.8B | 3.1B |
| Shareholder Equity | 3.8B | 3.6B | 3.8B | 3.5B | 3.1B |
| Total Debt | 1.7B | 1.6B | 1.7B | 2.0B | 2.1B |
| Net Debt | 815M | 946M | 1.0B | 1.3B | 1.2B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
639M
-10.7% YoY
Capital Expenditures
207M
-38.3% YoY
Free Cash Flow
432M
-23.6% YoY
Key ratios
Gross Margin
61.8%
Operating Margin
24.9%
Net Margin
20.3%
ROE
11.9%
Debt / Equity
0.44x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.